GYRE Financial Statements

Balance sheet, income statement, cash flow, and dividends for Gyre Therapeutics Inc (GYRE).


$1.13B Market Cap.

As of 03/17/2025 5:00 PM ET (MRY) • Disclaimer

GYRE Market Cap. (MRY)


GYRE Shares Outstanding (MRY)


GYRE Assets (MRY)


Total Assets

$125.41M

Total Liabilities

$27.00M

Total Investments

$43.80M

GYRE Income (MRY)


Revenue

$105.76M

Net Income

$12.09M

Operating Expense

$85.71M

GYRE Cash Flow (MRY)


CF Operations

-$3.64M

CF Investing

-$19.88M

CF Financing

$2.10M

GYRE Dividends (MRY)


Period

Dividends

Yield %

Growth %

Payout Ratio

Coverage Ratio

2024

$0

0%

0%

0%

-

2023

$3.60

14.00%

-83.22%

-255.32%

-0.39

2022

$21.45

271.10%

0%

-550.00%

-0.18

2021

$0

0%

0%

0%

-

2020

$0

0%

-

0%

-

GYRE Balance Sheet (MRY)


Metric

2024

2023

2022

2021

Total Assets

$125,406,000 (7.61%)

$116,539,000 (309.71%)

$28,444,000 (-48.90%)

$55,662,000 (-41.31%)

Assets Current

$64,786,000 (13.22%)

$57,221,000 (102.87%)

$28,206,000 (-45.21%)

$51,476,000 (-42.49%)

Assets Non-Current

$60,620,000 (2.19%)

$59,318,000 (24823.53%)

$238,000 (-94.31%)

$4,186,000 (-21.55%)

Goodwill & Intangible Assets

$1,705,000 (0.41%)

$1,698,000 (0%)

$0 (0%)

$0 (0%)

Shareholders Equity

$63,319,000 (500.04%)

-$15,828,000 (27.02%)

-$21,689,000 (-152.79%)

$41,089,000 (-45.98%)

Property Plant & Equipment Net

$25,698,000 (8.08%)

$23,777,000 (33867.14%)

$70,000 (-98.12%)

$3,714,000 (63.97%)

Cash & Equivalents

$11,813,000 (-64.75%)

$33,509,000 (54.66%)

$21,666,000 (-51.14%)

$44,347,000 (46.07%)

Accumulated Other Comprehensive Income

-$2,597,000 (-57.97%)

-$1,644,000 (0%)

$0 (0%)

$0 (0%)

Deferred Revenue

$989,000 (292.46%)

$252,000 (0%)

$0 (0%)

$230,000 (-88.40%)

Total Investments

$43,799,000 (86.93%)

$23,431,000 (0%)

$0 (0%)

$2,504,000 (-95.14%)

Investments Current

$19,231,000 (0%)

$0 (0%)

$0 (0%)

$2,504,000 (-94.89%)

Investments Non-Current

$24,568,000 (4.85%)

$23,431,000 (0%)

$0 (0%)

$0 (0%)

Inventory

$6,337,000 (48.03%)

$4,281,000 (0%)

$0 (0%)

$0 (0%)

Trade & Non-Trade Receivables

$24,780,000 (14.93%)

$21,561,000 (331.22%)

$5,000,000 (175.03%)

$1,818,000 (-45.13%)

Trade & Non-Trade Payables

$335,000 (-80.57%)

$1,724,000 (788.66%)

$194,000 (-96.98%)

$6,419,000 (8.23%)

Accumulated Retained Earnings (Deficit)

-$73,453,000 (14.13%)

-$85,538,000 (79.18%)

-$410,936,000 (-2.05%)

-$402,694,000 (-27.94%)

Tax Assets

$5,619,000 (19.68%)

$4,695,000 (0%)

$0 (0%)

$0 (0%)

Tax Liabilities

$2,831,000 (-43.98%)

$5,054,000 (0%)

$0 (0%)

$0 (0%)

Total Debt

$1,598,000 (290.71%)

$409,000 (976.32%)

$38,000 (-98.41%)

$2,385,000 (45.07%)

Debt Current

$713,000 (239.52%)

$210,000 (452.63%)

$38,000 (-98.08%)

$1,977,000 (198.19%)

Debt Non-Current

$885,000 (344.72%)

$199,000 (0%)

$0 (0%)

$408,000 (-58.41%)

Total Liabilities

$27,004,000 (-29.06%)

$38,065,000 (126.25%)

$16,824,000 (15.45%)

$14,573,000 (-22.39%)

Liabilities Current

$19,516,000 (-2.65%)

$20,047,000 (19.16%)

$16,824,000 (18.77%)

$14,165,000 (-20.40%)

Liabilities Non-Current

$7,488,000 (-58.44%)

$18,018,000 (0%)

$0 (0%)

$408,000 (-58.41%)

GYRE Income Statement (MRY)


Metric

2024

2023

2022

2021

Revenues

$105,757,000 (-6.78%)

$113,450,000 (14188.41%)

$794,000 (-89.18%)

$7,338,000 (-64.97%)

Cost of Revenue

$3,884,000 (-16.22%)

$4,636,000 (480.95%)

$798,000 (-89.19%)

$7,380,000 (-19.46%)

Selling General & Administrative Expense

$73,620,000 (-2.90%)

$75,821,000 (336.61%)

$17,366,000 (-8.42%)

$18,963,000 (17.20%)

Research & Development Expense

$12,024,000 (-12.74%)

$13,780,000 (5.70%)

$13,037,000 (-81.08%)

$68,889,000 (30.04%)

Operating Expenses

$85,710,000 (-51.31%)

$176,044,000 (1945.36%)

$8,607,000 (-90.20%)

$87,852,000 (27.04%)

Interest Expense

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Income Tax Expense

$5,320,000 (-37.52%)

$8,515,000 (2346.84%)

$348,000 (0%)

$0 (0%)

Net Loss Income from Discontinued Operations

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Consolidated Income

$17,898,000 (119.26%)

-$92,933,000 (-1027.55%)

-$8,242,000 (90.63%)

-$87,933,000 (-56.35%)

Net Income to Non-Controlling Interests

$5,813,000 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Net Income

$12,085,000 (113.00%)

-$92,933,000 (-1027.55%)

-$8,242,000 (90.63%)

-$87,933,000 (-56.35%)

Preferred Dividends Income Statement Impact

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Net Income Common Stock

$12,085,000 (113.00%)

-$92,933,000 (-1027.55%)

-$8,242,000 (90.63%)

-$87,933,000 (-56.35%)

Weighted Average Shares

$85,094,948 (29.26%)

$65,831,675 (3030.30%)

$2,103,048 (2.95%)

$2,042,732 (59.76%)

Weighted Average Shares Diluted

$102,293,526 (55.39%)

$65,831,675 (3030.30%)

$2,103,048 (2.95%)

$2,042,732 (59.76%)

Earning Before Interest & Taxes (EBIT)

$17,405,000 (120.62%)

-$84,418,000 (-969.39%)

-$7,894,000 (91.02%)

-$87,933,000 (-56.35%)

Gross Profit

$101,873,000 (-6.38%)

$108,814,000 (2720450.00%)

-$4,000 (90.48%)

-$42,000 (-100.36%)

Operating Income

$16,163,000 (124.04%)

-$67,230,000 (-680.75%)

-$8,611,000 (90.20%)

-$87,894,000 (-53.21%)

GYRE Cash Flow Statement (MRY)


Metric

2024

2023

2022

2021

Net Cash Flow from Investing

-$19,884,000 (-0.63%)

-$19,760,000 (-135.65%)

$55,426,000 (15.02%)

$48,189,000 (398.70%)

Net Cash Flow from Financing

$2,102,000 (-15.92%)

$2,500,000 (105.55%)

-$45,011,000 (-190.83%)

$49,553,000 (-17.93%)

Net Cash Flow from Operations

-$3,641,000 (-114.06%)

$25,892,000 (178.23%)

-$33,096,000 (60.48%)

-$83,755,000 (-52.15%)

Net Cash Flow / Change in Cash & Cash Equivalents

-$21,696,000 (-360.33%)

$8,334,000 (136.74%)

-$22,681,000 (-262.16%)

$13,987,000 (-6.70%)

Net Cash Flow - Business Acquisitions and Disposals

$0 (0%)

$4,897,000 (-90.66%)

$52,424,000 (0%)

$0 (0%)

Net Cash Flow - Investment Acquisitions and Disposals

-$17,157,000 (-2.52%)

-$16,735,000 (-768.33%)

$2,504,000 (-94.89%)

$49,028,000 (393.74%)

Capital Expenditure

-$1,914,000 (75.63%)

-$7,853,000 (-1676.91%)

$498,000 (159.36%)

-$839,000 (-214.23%)

Issuance (Repayment) of Debt Securities

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Issuance (Purchase) of Equity Shares

$2,638,000 (0%)

$0 (0%)

$20,000 (-99.96%)

$49,553,000 (-17.93%)

Payment of Dividends & Other Cash Distributions

$0 (0%)

$0 (0%)

-$45,031,000 (0%)

$0 (0%)

Effect of Exchange Rate Changes on Cash

-$273,000 (8.39%)

-$298,000 (0%)

$0 (0%)

$0 (0%)

Share Based Compensation

$831,000 (-88.59%)

$7,281,000 (442.55%)

$1,342,000 (-60.59%)

$3,405,000 (-6.12%)

Depreciation Amortization & Accretion

$2,221,000 (55.42%)

$1,429,000 (521.30%)

$230,000 (-20.69%)

$290,000 (110.14%)

GYRE Financial Metrics (MRY)


Metric

2024

2023

2022

2021

Gross Margin

96.30% (0.42%)

95.90% (19280.00%)

-0.50% (16.67%)

-0.60% (-101.07%)

Profit Margin

11.40% (113.92%)

-81.90% (92.11%)

-1038.00% (13.38%)

-1198.30% (-346.29%)

EBITDA Margin

18.60% (125.41%)

-73.20% (92.42%)

-965.20% (19.19%)

-1194.40% (-346.00%)

Return on Average Equity (ROAE)

19.90% (-96.44%)

558.30% (2025.17%)

-29.00% (75.99%)

-120.80% (-102.35%)

Return on Average Assets (ROAA)

9.80% (104.16%)

-235.80% (-1210.00%)

-18.00% (81.84%)

-99.10% (-94.31%)

Return on Sales (ROS)

16.50% (122.18%)

-74.40% (92.52%)

-994.20% (17.03%)

-1198.30% (-346.29%)

Return on Invested Capital (ROIC)

19.90% (104.37%)

-455.50% (-158.90%)

773.40% (194.24%)

-820.70% (-637.38%)

Dividend Yield

0% (0%)

14.00% (-94.84%)

271.10% (0%)

0% (0%)

Price to Earnings Ratio (P/E)

86.43 (574.36%)

-18.22 (-797.98%)

-2.03 (-538.05%)

-0.32 (85.24%)

Price to Sales Ratio (P/S)

9.74 (-34.69%)

14.91 (-28.87%)

20.96 (449.07%)

3.82 (-33.93%)

Price to Book Ratio (P/B)

17.87 (534.95%)

-4.11 (-436.42%)

-0.77 (-209.59%)

0.7 (-61.87%)

Debt to Equity Ratio (D/E)

0.43 (117.71%)

-2.4 (-209.92%)

-0.78 (-318.59%)

0.35 (43.72%)

Earnings Per Share (EPS)

0.14 (109.93%)

-1.41 (63.85%)

-3.9 (90.94%)

-43.05 (2.05%)

Sales Per Share (SPS)

1.24 (-27.86%)

1.72 (355.82%)

0.38 (-89.48%)

3.59 (-78.07%)

Free Cash Flow Per Share (FCFPS)

-0.07 (-123.72%)

0.27 (101.77%)

-15.5 (62.57%)

-41.41 (4.27%)

Book Value Per Share (BVPS)

0.74 (410.00%)

-0.24 (97.67%)

-10.31 (-151.27%)

20.11 (-66.19%)

Tangible Assets Book Value Per Share (TABVPS)

1.45 (-16.63%)

1.74 (-87.11%)

13.53 (-50.37%)

27.25 (-63.27%)

Enterprise Value Over EBIT (EV/EBIT)

64 (6500.00%)

-1 (-200.00%)

1 (0%)

0 (0%)

Enterprise Value Over EBITDA (EV/EBITDA)

56.94 (7622.06%)

-0.76 (-195.10%)

0.8 (148.75%)

0.32 (115.48%)

Asset Turnover

0.86 (-70.23%)

2.88 (16835.29%)

0.02 (-79.52%)

0.08 (-56.32%)

Current Ratio

3.32 (16.33%)

2.85 (70.18%)

1.68 (-53.85%)

3.63 (-27.75%)

Dividends

$0 (0%)

$3.6 (-83.22%)

$21.45 (0%)

$0 (0%)

Free Cash Flow (FCF)

-$5,555,000 (-130.79%)

$18,039,000 (155.34%)

-$32,598,000 (61.47%)

-$84,594,000 (-52.93%)

Enterprise Value (EV)

$1,117,538,351 (1679.07%)

$62,815,898 (1130.11%)

-$6,097,997 (78.26%)

-$28,054,528 (-124.19%)

Earnings Before Tax (EBT)

$17,405,000 (120.62%)

-$84,418,000 (-969.39%)

-$7,894,000 (91.02%)

-$87,933,000 (-56.35%)

Earnings Before Interest Taxes & Depreciation Amortization (EBITDA)

$19,626,000 (123.65%)

-$82,989,000 (-982.84%)

-$7,664,000 (91.26%)

-$87,643,000 (-56.22%)

Invested Capital

$93,970,000 (52.32%)

$61,694,000 (716.45%)

-$10,008,000 (-2052.26%)

-$465,000 (-100.96%)

Working Capital

$45,270,000 (21.78%)

$37,174,000 (226.60%)

$11,382,000 (-69.49%)

$37,311,000 (-47.97%)

Tangible Asset Value

$123,701,000 (7.72%)

$114,841,000 (303.74%)

$28,444,000 (-48.90%)

$55,662,000 (-41.31%)

Market Capitalization

$1,131,609,351 (1639.76%)

$65,043,898 (291.57%)

$16,611,003 (-42.14%)

$28,708,472 (-79.41%)

Average Equity

$60,872,250 (465.72%)

-$16,644,500 (-158.49%)

$28,458,000 (-60.89%)

$72,769,500 (-22.71%)

Average Assets

$123,396,250 (213.10%)

$39,411,750 (-13.91%)

$45,777,500 (-48.43%)

$88,765,250 (-19.47%)

Invested Capital Average

$87,415,500 (371.67%)

$18,533,000 (1915.63%)

-$1,020,750 (-109.53%)

$10,714,500 (-78.80%)

Shares

93,521,434 (3593.76%)

2,531,876 (20.60%)

2,099,337 (0.26%)

2,093,980 (42.14%)